Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CCNC | P24863 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 2/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.33 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24408840 | 0.83 | HTR2A (0.42) | SIGMAR1DRD2HTR2ASCD | |
| SCHEMBL24408813 | 0.83 | CHRNB2 (0.41) | SIGMAR1CHRNB2CHRNA4CCNCCDK8 | |
| SCHEMBL2077983 | 0.73 | SIGMAR1 (0.57) | SIGMAR1DRD2HTR2ASCD | |
| SCHEMBL30376964 | 0.73 | SIGMAR1 (0.57) | SIGMAR1DRD2HTR2ASCD | |
| SCHEMBL23811371 | 0.71 | CHRNB2 (0.43) | SIGMAR1CHRNB2CHRNA4CCNCCDK8 | |
| SCHEMBL21142848 | 0.71 | CHRNB2 (0.47) | SIGMAR1CHRNB2CHRNA4CCNCCDK8 | |
| SCHEMBL24408853 | 0.70 | KMT2A (0.36) | — | |
| SCHEMBL20747125 | 0.70 | KDM4E (0.49) | SIGMAR1CCNCCDK8HASPINCDK19 | |
| SCHEMBL18020472 | 0.70 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNA4HTR2ACHRNA7 | |
| SCHEMBL3560241 | 0.69 | SIGMAR1 (0.57) | SIGMAR1DRD2HTR2ASCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | SIGMAR1 816/4885CHRNB2 41/4885CHRNA4 56/4885 |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | SIGMAR1 708/4885CHRNB2 51/4885CHRNA4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.